NCT06584812 - Study to Assess Pharmacokinetics, Pharmacodynamics and Safety of Tiprogrel in Healthy Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 9, 2024

Primary Completion Date

December 5, 2024

Study Completion Date

December 17, 2024

Conditions

Acute Coronary SyndromeIschemic Stroke

Interventions

DRUG

Tiprogrel

Period 1: Dose 1 Tiprogrel, loading dose of Tiprogrel followed by daily maintenance dose until Day 8.

DRUG

Tiprogrel

Period 2: Dose 2 Tiprogrel ; loading dose of Tiprogrel followed by daily maintenance dose until Day 8.

DRUG

Clopidogrel

Period 3: Clopidogrel; loading dose of Clopidogrel followed by daily maintenance dose until Day 8.

DRUG

Ticagrelor

Period 4: Ticagrelor; loading dose of Ticagrelor followed by daily maintenance dose until Day 8.

Trial Locations (1)

Beijing Tiantan Hosptial, Capital Medical University, Beijing

All Listed Sponsors

lead

Tianjin Institute of Pharmaceutical Research Co., Ltd

OTHER_GOV